ClinicalTrials.gg
TerminatedNCT06511947Updated Oct 9, 2026

Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

A Phase 1 interventional study of 5 Methoxy N,N Dimethyltryptamine in Healthy Volunteers, sponsored by GH Research Ireland Limited. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by GH Research Ireland Limited · Phase 1, Interventional, and Treatment

Why this study was terminated
The Sponsor elected to stop the trial after Part 1 and 2, having determined the scientific objective was met with sufficient data to select doses for future trials. Not driven by safety, tolerability, or recruitment; all subjects completed the trial.
Updated Oct 9, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This is an open-label Phase 1 trial in healthy subjects designed to characterize the pharmacokinetic (PK) profile, pharmacodynamics, and safety and tolerability of GH001 (mebufotenin) delivered via the GH001 Aerosol Delivery System (ADS).

The trial is conducted in three parts. In Part 1, subjects receive a single dose of GH001 via the ADS. In Part 2, subjects receive GH001 via both the ADS and the Volcano Medic 2 Vaporization System in a crossover design, to estimate the relative bioavailability of mebufotenin between the two delivery systems. In Part 3, subjects receive a single-day individualized dosing regimen (IDR) of GH001 via the ADS, in which up to three increasing doses are given at approximately 1-hour intervals.

The primary objectives are to determine the serum PK profile of mebufotenin and its metabolites and to evaluate the safety and tolerability of GH001 across these parts. Secondary objectives include characterizing the pharmacodynamic profile, as assessed by its psychoactive effects (PsE) and effects on cognitive performance, and estimating the time for the maximum serum concentration (Cmax) to decline by 50% and 90% (tCmax/2 and tCmax/10).

Part 3 of this trial was not initiated. The trial was terminated after Part 2.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Mebufotenin
  • 5-MeO-DMT
  • 5-methoxy-N,N-dimethyltryptamine
  • GH001
  • Healthy volunteers
  • Pharmacokinetics
03

In context

Lead sponsor

GH Research Ireland Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) in the range of 18.5 to 35 kg/m2 (inclusive) at screening
  • Good mental health in the opinion of the investigator.
  • Normal spirometry ( of >80% of predicted and FVC of >80% of predicted value) at screening.

Exclusion criteria

Exclusion Criteria:

  • Has known allergies or or any other to mebufotenin, bufotenin, melatonin or triptans.
  • Has received any medication, including investigational vaccines, in the 3 months prior to baseline or is in the follow-up period of another clinical trial at the time of screening for this trial.
  • Has a current or past condition, which renders the subject unsuitable for the trial according to the investigator's judgement.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Part 1, Cohort A

    A single inhaled dose of 6 mg GH001 administered via a proprietary aerosol delivery device in eight subjects.

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 1, Cohort B

    A single inhaled dose of 12 mg GH001 administered via a proprietary aerosol delivery device in eight subjects.

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 1, Cohort C

    A single inhaled dose of GH001 administered via a proprietary aerosol delivery device in eight subjects.

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 1, Cohort D (optional)

    A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts A, B, and C).

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 1, Cohort E (optional)

    A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts A, B, and C).

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 1, Cohort F (optional)

    A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts D and E).

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 1, Cohort G (optional)

    A single inhaled intermediate dose of GH001 administered via a proprietary aerosol delivery device in eight subjects (optional cohort dependent on study safety group \[SSG\] review of PK, PD, and safety data from Cohorts D and E).

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 2, Cohort H

    A single-sequence crossover cohort of 12 subjects. Each subject receives a single inhaled dose of 6 mg GH001 administered via the Volcano Medic 2 Vaporization System in Treatment Period 1, followed by a single inhaled dose of 6 mg GH001 administered via a proprietary aerosol delivery device in Treatment Period 2, with 14 days between the dosing day of each treatment period.

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 2, Cohort I

    A randomized, two-sequence crossover cohort of up to 16 subjects. Each subject is randomly assigned to a device administration sequence and receives a single inhaled dose of 6 mg GH001 via the Volcano Medic 2 Vaporization System and a single inhaled dose of GH001 via a proprietary aerosol delivery device across two treatment periods, with 14 days between the dosing day of each treatment period. The dose administered via the proprietary aerosol delivery device is determined by the study safety group (SSG) to achieve systemic exposure comparable to 6 mg GH001 administered via the Volcano Medic 2 Vaporization System.

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 3, Cohort J

    An individualized dosing regimen (IDR) of GH001 administered via a proprietary aerosol delivery device on a single day in 12 subjects. Up to three escalating doses are administered at approximately 1-hour intervals. The second and third doses are administered only if a peak experience was not achieved after the previous dose, the previous dose was satisfactorily tolerated, any psychoactive effects of the previous dose have substantially subsided, and vital signs and FEV1 are acceptable. This cohort was not initiated. The trial was terminated after Part 2.

    Drug: 5 Methoxy N,N Dimethyltryptamine

  • Experimental
    Part 3, Cohort K (optional)

    An optional individualized dosing regimen (IDR) cohort of 12 subjects, identical in design to Cohort J, administered via a proprietary aerosol delivery device. Enrolled only if safety, PK, and PD data from Cohort J indicate further exploration is needed (dependent on study safety group \[SSG\] review). This cohort was not initiated. The trial was terminated after Part 2.

    Drug: 5 Methoxy N,N Dimethyltryptamine

Interventions

06

What researchers measure

Primary outcomes

  1. Serum PK parameters of mebufotenin - maximum observed concentration (Cmax)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  2. Serum PK parameters of mebufotenin - time of maximum observed concentration (Tmax)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  3. Serum PK parameters of mebufotenin - terminal elimination half-life (t1/2)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  4. Serum PK parameters of mebufotenin - area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUClast)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  5. Serum PK parameters of mebufotenin - area under the serum concentration-time curve extrapolated to infinity (AUCinf)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  6. Serum PK parameters of mebufotenin - partial area under the curve between t1 and t2 (AUCt1-t2)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  7. Serum PK parameters of mebufotenin - terminal elimination rate constant (λz)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  8. Serum PK parameters of mebufotenin - apparent total body clearance (CL/F)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  9. Serum PK parameters of mebufotenin - apparent volume of distribution (up to bioavailability) after extravascular administration (Vz/F)

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  10. Serum PK parameters of mebufotenin - Cmax/AUCinf

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH001 to determine mebufotenin serum concentrations.

    Time frame: Up to 6 hours

  11. Safety and tolerability: incidence of treatment-emergent adverse events

    Adverse events reported in the study and coded by MedDRA.

    Time frame: Up to 7 days

  12. Safety and tolerability: clinically significant changes from baseline in electrocardiogram (ECG), vital signs, spirometry and safety laboratory assessments

    Percentage of subjects with clinically significant changes\* from baseline in ECG (heart rate, RR, QT, PR, and QRS intervals, and QTcF). Percentage of subjects with clinically significant changes\* from baseline in vital signs (systolic and diastolic blood pressure, respiration rate, heart rate, peripheral oxygen saturation, body temperature). Percentage of subjects with clinically significant changes\* from baseline in spirometry (forced expiratory volume in 1 second \[FEV1\] and forced vital capacity \[FVC\]). Percentage of subjects with clinically significant changes\* from baseline in safety laboratory assessments (hematology, biochemistry, and urinalysis). \*Clinically significant changes as determined by the principal investigator

    Time frame: Up to 7 days

  13. Safety and tolerability: assessment of sedation (Modified Observer's Assessment of Alertness and Sedation [MOAA/S]) following each dose and as part of the discharge evaluation on Day 0

    The MOAA/S will be completed before and after GH001 dosing. Scored from 0 (deep sedation) to 5 (alert).

    Time frame: Postdose, up to discharge on dosing day (Day 0)

  14. Safety and tolerability: change from baseline in Clinician Administered Dissociative States Scale (CADSS)

    The CADSS comprises 19 subjective items, ranging from 0 'not at all' to 4 'extremely'. Summed together, these subscales form a total dissociative score. Combined score ranges from 0 to 76.

    Time frame: From baseline up to 7 days

  15. Safety and tolerability: assessment of subject discharge readiness at discharge on Day 0

    Assessment of Discharge Readiness on the administration day by the principal investigator, using the Clinical Assessment of Discharge Readiness (CADR).

    Time frame: Postdose, at discharge on dosing day (Day 0)

  16. Safety and tolerability: Columbia-Suicide Severity Rating Scale (C-SSRS) categorization.

    A detailed questionnaire assessing both suicidal behaviour and suicidal ideation.

    Time frame: Up to 7 days

  17. Safety and tolerability: Change from baseline in Brief Psychiatric Rating Scale (BPRS).

    A scale to measure psychiatric symptoms. Each symptom is rated 1-7 and a total of 18 symptoms are scored. Combined score ranges from 18 to 126 and a higher score means a worse outcome.

    Time frame: From baseline up to 7 days

  18. Estimate of the relative bioavailability for Cmax, AUClast, AUCinf, and AUCt1-t2 of mebufotenin

    Estimate of the relative bioavailability between the GH001 ADS and Volcano Medic 2 Vaporization System for Cmax, AUClast, AUCinf, and AUCt1-t2 of mebufotenin

    Time frame: Up to 6 hours

07

Study locations

1 site
  • GH Research Clinical Trial Site
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2024 to primary completion in Mar 2026, 19 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Feb 2025 → Mar 2026 and completion Feb 2025 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2024
First posted
Jul 22, 2024
StartActual
Aug 1, 2024
Primary completionActual
Mar 23, 2026was Feb 2025
CompletionActual
Mar 23, 2026was Feb 2025
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated The Sponsor elected to stop the trial after Part 1 and 2, having determined the scientific objective was met with sufficient data to select doses for future trials. Not driven by safety, tolerability, or recruitment; all subjects completed the trial.
changed Oct 9, 2026
Primary completion
Feb 2025→Mar 23, 2026 (actual)
Oct 9, 2026
Study completion
Feb 2025→Mar 23, 2026 (actual)
Oct 9, 2026
Enrollment
52 (estimated)→71 (actual)
Oct 9, 2026
Interventions
Arm changed Part 2, Cohort F→Part 1, Cohort F (optional). Arms added: Part 1, Cohort G (optional)·Part 2, Cohort H·Part 2, Cohort I·Part 3, Cohort J·Part 3, Cohort K (optional)
Oct 9, 2026
Primary outcomes
4 edited, 2 added, 1 description edited
What changed in the outcomes
  • EditedSerum PK parameters of mebufotenin - area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUC0-tAUClast)Time frame: Up to 6 hours
  • EditedSerum PK parameters of mebufotenin - area under the serum concentration-time curve extrapolated to infinity (AUC0-∞AUCinf)Time frame: Up to 6 hours
  • EditedSerum PK parameters of mebufotenin - apparent steady-state volume of distribution (VSSup to bioavailability) after extravascular administration (Vz/F)Time frame: Up to 6 hours
  • EditedSerum PK parameters of mebufotenin - Cmax/AUC0-∞AUCinfTime frame: Up to 6 hours
  • AddedSerum PK parameters of mebufotenin - partial area under the curve between t1 and t2 (AUCt1-t2)Time frame: Up to 6 hours
  • AddedEstimate of the relative bioavailability for Cmax, AUClast, AUCinf, and AUCt1-t2 of mebufoteninTime frame: Up to 6 hours
  • DescriptionSafety and tolerability: change from baseline in Clinician Administered Dissociative States Scale (CADSS): how it is measured was reworded
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Terminated
    Why stopped The Sponsor elected to stop the trial after Part 1 and 2, having determined the scientific objective was met with sufficient data to select doses for future trials. Not driven by safety, tolerability, or recruitment; all subjects completed the trial.
    Primary completion Feb 2025→Mar 23, 2026 (now actual)
    Study completion Feb 2025→Mar 23, 2026 (now actual)
    Enrollment 52 (estimated)→71 (actual)
    Primary outcomes 4 edited, 2 added, 1 description edited
    What changed in the outcomes
    • EditedSerum PK parameters of mebufotenin - area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUC0-tAUClast)Time frame: Up to 6 hours
    • EditedSerum PK parameters of mebufotenin - area under the serum concentration-time curve extrapolated to infinity (AUC0-∞AUCinf)Time frame: Up to 6 hours
    • EditedSerum PK parameters of mebufotenin - apparent steady-state volume of distribution (VSSup to bioavailability) after extravascular administration (Vz/F)Time frame: Up to 6 hours
    • EditedSerum PK parameters of mebufotenin - Cmax/AUC0-∞AUCinfTime frame: Up to 6 hours
    • AddedSerum PK parameters of mebufotenin - partial area under the curve between t1 and t2 (AUCt1-t2)Time frame: Up to 6 hours
    • AddedEstimate of the relative bioavailability for Cmax, AUClast, AUCinf, and AUCt1-t2 of mebufoteninTime frame: Up to 6 hours
    • DescriptionSafety and tolerability: change from baseline in Clinician Administered Dissociative States Scale (CADSS): how it is measured was reworded
    Interventions Arm changed Part 2, Cohort F→Part 1, Cohort F (optional). Arms added: Part 1, Cohort G (optional)·Part 2, Cohort H·Part 2, Cohort I·Part 3, Cohort J·Part 3, Cohort K (optional)
    + 6 other changes: index terms, verification date, description, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06511947
Lead sponsor
GH Research Ireland Limited
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Aug 1, 2024
Primary completion
Mar 23, 2026
Completion
Mar 23, 2026
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxydimethyltryptamines

Start the discussion